IN2SIGHT is a project that fosters an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials. This technology will recast our thinking of biomaterial validation, allowing unprecedented quantitative and longitudinal analyses of the host inflammatory response to the implant.
The project will allow unique quantification of the immune reaction to biomaterials at the cellular level (scientific impact), largely reducing the ethical burden of the research and the costs of biomaterial discovery (economical impact), and will Refine and Reduce protocols for biocompatibility on a single revolutionary device (regulatory impact).
Yesterday, Marta Rayo Lunar and Luis Borges Rocha represented Asphalion at the 6-month consortium meeting of IN2SIGHT, an H2020 funded project, which took place online.
In the meeting, they had the opportunity to share Asphalion´s first deliverable with the other project partners.
For more information about the IN2SIGHT the project, including a short presentation video, we invite you to visit the project website: https://www.in2sight.eu/.
For any further information, you can contact us at: horizon@asphalion.com
